Insider trade

Processa Pharmaceuticals (PCSA): Officer exercised options on 193 units

Patrick Lin, Officer at Processa Pharmaceuticals, reported an option exercise of 193 units.

193
Derivative units
Traded
Jan 1, 2026
Filed
Feb 5, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 12, 2025Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year

What came next

  1. Feb 12, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  2. Mar 31, 2026Insider · 9 peopleInsiders: 9 purchases (~$43K)
  3. Apr 15, 2026Insider · 5 peopleInsiders: 5 purchases (~$25K)
  4. Apr 30, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Processa Pharmaceuticals

OQRO holds no insider, Congress, fund or contract record for Processa Pharmaceuticals dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its PCSA page.

Other recent filings by Patrick Lin, Chief Business - Strategy Off

The full history of Patrick Lin, Chief Business - Strategy Off is on the profile page.

How this filing works

Explore the data

Common questions

Which Processa Pharmaceuticals (PCSA) insider traded, and how much?

Patrick Lin, Officer at Processa Pharmaceuticals, reported an option exercise of 193 units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jan 1, 2026. Filed: Feb 5, 2026. That is 35 days between the two dates.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

Does this mean PCSA stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Processa Pharmaceuticals

Everything OQRO holds on this company is on its PCSA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data